A tissue-targeted prime/pull/keep therapeutic herpes simplex virus vaccine protects against recurrent ocular herpes infection and disease in HLA-A*0201 transgenic rabbits.

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Lbachir BenMohamed, Aziz A Chentoufi, Sweta Karan, Anthony B Nesburn, Swayam Prakash, Afshana Quadiri, Hawa Vahed

Ngôn ngữ: eng

Ký hiệu phân loại: 011.532 *Government publications issued by legislative bodies and their committees

Thông tin xuất bản: United States : Journal of virology , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 742898

Thêm vào giỏ Liên kết toàn văn

UNLABELLED: Herpes simplex virus type 1 (HSV-1) continues to be one of the most prevalent viral infections globally, with approximately 3.72 billion individuals affected worldwide. A clinical herpes vaccine is still lacking. In the present study, a novel prime/pull/keep vaccine was tested in a human leukocyte antigen transgenic rabbit model of ocular herpes (HLA-A*0201 Tg rabbit). Ten asymptomatic (ASYMP) CD8 IMPORTANCE: There is an urgent need for a vaccine against widespread human herpes simplex virus infections. The present study demonstrates that immunization of humanized HLA-A*0201 transgenic rabbits with CD8

Tạo bộ sưu tập với mã QR